tbuckley/cabot-search huggingface dataset:
Regulation of integrin α5 and β4 in normal and scleroderma epidermal keratinocytes
Authors: J. Zhou, X-Y. Man, W. Li, J-Q. Chen, S-Q. Cai, M. Zheng
Journal: British Journal of Dermatology (2012)

Journal Article Regulation of integrin α5 and β4 in normal and scleroderma epidermal keratinocytes Get access J. Zhou, J. Zhou Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China Search for other works by this author on: Oxford Academic Google Scholar X‐Y. Man, X‐Y. Man Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China Search for other works by this author on: Oxford Academic Google Scholar W. Li, W. Li Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China Search for other works by this author on: Oxford Academic Google Scholar J‐Q. Chen, J‐Q. Chen Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China Search for other works by this author on: Oxford Academic Google Scholar S‐Q. Cai, S‐Q. Cai Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China Search for other works by this author on: Oxford Academic Google Scholar M. Zheng M. Zheng Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China Min Zheng. E‐mail: minz@zju.edu.cn Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 166, Issue 6, 1 June 2012, Pages 1369–1370, https://doi.org/10.1111/j.1365-2133.2012.10795.x Published: 01 June 2012
Why Stop at Using High-Dose-Rate Brachytherapy as a Boost for the Prostate?
Authors: Jonathan Beitler
Journal: Journal of Clinical Oncology (2000)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.23.4003 Journal of Clinical Oncology - published online before print September 21, 2016 Why Stop at Using High-Dose-Rate Brachytherapy as a Boost for the Prostate? Jonathan BeitlerxJonathan BeitlerSearch for articles by this author Show More Montefiore Medical Center The Albert Einstein Cancer Center Bronx, NY https://doi.org/10.1200/JCO.2000.18.23.4003 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma
Authors: Jon M. Richards, Danielle Gale, Nilesh Mehta, Timothy Lestingi
Journal: Journal of Clinical Oncology (1999)

PURPOSE: The primary objective of this clinical study was to assess the feasibility of administering recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxic chemotherapy. After encouraging initial responses, the study was expanded to further evaluate the therapeutic potential, clarify the toxicities of this regimen, and explore any associated immunologic changes. PATIENTS AND METHODS: Eighty-four patients with metastatic melanoma, including patients with brain metastases, were treated on this 6-week protocol. Patients received combination cisplatin (25 mg/m 2 /d) and dacarbazine (220 mg/m 2 /d) on days 1 through 3 and 22 through 24 plus carmustine (150 mg/m 2 ) on day 1. Interleukin 2 (13.5 million IU/m 2 /d) and interferon alfa (6 MU/m 2 /d) were administered on days 4 through 8 and 17 through 21. RESULTS: Among 83 patients assessable for response, 12 complete and 34 partial responses were documented (55% response rate). The median time to disease progression was 7 months, the median survival from study entry was 12.2 months, and the median survival from diagnosis of metastatic disease was 15.5 months. Although patients were hospitalized to receive treatment, intensive care unit support generally was not needed. Dose-limiting toxicities were related to elevations in serum bilirubin and serum creatinine levels. No patient developed a grade 4 clinical toxicity. Treatment produced a skin depigmentation, which was associated with prolonged survival. CONCLUSION: A plateau in both the survival and time to progression curves beyond 2 years (15% of the patients) and a greater than 10% disease-free survival beyond 4 years indicate that there may be a long-term benefit for some patients. The limited toxicity of this regimen should permit its use in most oncology settings. A randomized trial of chemoimmunotherapy versus chemotherapy should be performed to establish the value of chemoimmunotherapy for melanoma.
A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study.
Authors: Thomas Cheung Yau, Foon Yiu Cheung, Francis Lee, Su Pin Choo, Hilda Wong, Han Chong Toh, A. K. Leung, Pierre Chan, T. K. Yau, Joyce Wong, Y. F. Tang, Sze Man June Lau, Tan To Cheung, Sheung Tat Fan, Ronnie Tung Ping Poon
Journal: Journal of Clinical Oncology (2013)

4117 Background: This is a single arm, multi-center, phase II study to assess the efficacy and tolerability of sorafenib, oxaliplatin and capecitabine combination for the treatment of advanced hepatocellular carcinoma (HCC) patients. Methods: Eligible patients received SECOX regime—sorafenib 400 mg bid (Day one-fourteen), oxaliplatin 85 mg/m 2 (Day one) and capecitabine 1700 mg/m 2 (Day one-seven) every two weeks. Response assessment was based on RECIST 1.0 criteria. The primary endpoint was time-to-progression (TTP) and the secondary endpoints were tumor response rate (RR), progression-free survival (PFS), overall survival (OS) and tolerability. Results: A total of 51 patients were enrolled in the trial.The median age was 58 years (range, 28-81) and 84% of patients were chronic hepatitis B carriers. Ninety percent of recruited patients belonged to BCLC stage C disease and 41 (80%) patients had extra-hepatic metastasis. The best RR was 16% and they were all partial response. Another 62% of patients achieved stable disease for at least eight weeks. The median TTP was 5.29 months (95% CI 3.81-5.88 months), PFS 5.26 months (95% CI 3.75-5.88 months) and OS was 11.73 months (95% CI 8.87- 15.38 months). Diarrhea (75%), Hand-foot-skin reaction (73%) and transient liver function derangement were the most commonly encountered adverse events, with the majority of patients having grade one or two. No treatment-related death was reported. Conclusions: The SECOX regime indicates preliminary promising activity and safety in Asian population with advanced HCC. Our data support a randomized trial comparing SECOX versus sorafenib alone for treatment of advanced HCC. Clinical trial information: NCT00752063.
Prevalence of COPD in a sub-Saharan country: Fresh Air Uganda survey
Authors: Frederik van Gemert, Bruce Kirenga, Niels Chavannes, Moses Kamya, Simon Luzige, Patrick Musinguzi, Rupert Jones, Ioanna Tsiligianni, Sian Williams, Corina de Jong, Thys van der Molen
Journal: European Respiratory Journal (2014)

Aim   To collect data on prevalence of COPD and related risk factors in a rural area of Uganda.   Methods   Population-based cross-sectional epidemiological survey of randomly selected subjects above age of 30. Trained local healthcare workers used validated questionnaires, and performed pre- and post-bronchodilator spirometry. The lower limit of normal threshold, i.e. below the fifth percentile of the predicted FEV 1 /FVC ratio, was used as defining criterion of COPD.   Results   Subjects (n=588) mean age: 45 (SD ± 13.7), 50.5% women; 93% exposed to indoor biomass smoke (men: 91%, mean 3.1 hours/day; women: 95%, mean 5.2 hours/day); 94% used kerosene lamps. The prevalence of COPD was 16.2% (53% women): 78% GOLD 1, 20% GOLD 2, and 2% GOLD 3. Prevalence was highest in group 30-39 years: 38% of men and 40% of women.  In the COPD group, men 44% current and 24% former smokers; women 8% current and 18% former smokers. Total mean Clinical COPD Questionnaire (CCQ) 0.81 (SD ± 0.78) and MRC dyspnoea score 1.33 (SD ± 0.65); 30% had one or more exacerbations during last 12 months, increasing with age.  In multiple regression analyses, only a few factors were found to be associated with COPD: wheeze OR 2.19 (95%CI: 1.09-4.37;p=0.026), cough OR 1.64 (95%CI: 0.96-2.78;p=0.068), heart failure OR 2.53 (95%CI: 0.99-6.50;p=0.054), current smoker OR 1.65 (95%CI: 0.95-2.88;p=0.078), and former smoker OR 1.93 (95%CI: 1.05-3.52;p=0.033).   Conclusion   In Uganda, the prevalence of COPD is high, especially in lower age groups. In addition to a high smoking prevalence in men, biomass smoke exposure is almost uniform in this population. With a life expectancy of 52 years, COPD represents a major threat to men and women of all ages in rural areas of Uganda.
Chemotherapy using S-1 plus low dose CDDP after noncurative surgery for stage III and IV advanced gastric cancer
Authors: N. Takahashi, H. Nimura, N. Mitsumori, K. Aiba, K. Yanaga
Journal: Journal of Clinical Oncology (2005)

4255 Background: S-1, an active oral drug against advanced gastric cancer combined with CDDP achieved >70% response rate in Japan. We herein report the preliminary results of S-1 plus low dose CDDP as the post operative therapy in the Stage III and IV gastric cancer. Methods: We enrolled 16 patients in the outpatient clinic between July 2002 and June 2004. All had adequate PS and bone marrow, renal as well as hepatic functions. Non had prior chemotherapy after surgery. Every three weeks, patients received S-1 80 mg/m2 orally twice daily on days 1–14 plus fractionated cisplatin 15 mg/m2 i.v. on days 1 and 8. Results: Baseline characteristics of the 16 patients have been enrolled to date: 12 men, 4 women; median age 55.6 (range 28–77) years; 68.8% of pts had Stage IV gastric cancer. The median treatment duration is currently 6.4 cycles (range 1–14). Four patients died of recurrent disease (25.0%) and 1 died of other (non-malignant) causes (6.3%). Median follow-up was 332.3 (range 123 to 781) days and median progression-free time is 327 days. Overall survival has not yet been reached. The most common toxicity was neutropenia (16.7% grade 3, 33.3% Grade 2); thrombocytopenia (8.3% grade 3, 25% grade 2). There were no grade 4 and very few grade 3 adverse events: nausea, vomiting, anemia, diarrhea, anorexia and pigmentation. Most events were easily managed with dose adjustment and/or suitable treatments. Conclusions: Our preliminary results suggest that postoperative S-1 plus low dose CDDP is safe and well-tolerated for patients with noncurative resection of gastric cancer, which can be given as an outpatient. Median progression-free time is 327 days meaningful result for this type of patients setting. Longer follow up and further studies are needed to evaluate efficacy. No significant financial relationships to disclose.
Rhythm control decreased severity of sleep-disordered breathing in patients with atrial fibrillation following cardioversion
Authors: Henrik Fox, Thomas Bitter, Dieter Horstkotte, Olaf Oldenburg
Journal: European Respiratory Journal (2013)

To date Sleep-disordered breathing (SDB) is recognized as an independent risk factor for the development of atrial fibrillation (Afib) and re-occurrence of Afib after cardioversion and/or ablative therapies. Thus, little is known about the influence of successful restoring of sinus rhythm on SDB’s severity.  A total of 45 patients (30 males, 15 females, mean age 67 years) with Afib (n = 40) or atrial flutter (Aflu) (n = 5) were investigated for the presence and severity of SDB by multichannel cardiorespiratory polygraphy (PG) before and after successful synchronized electrical cardioversion into stable sinus rhythm.  Apnoea-hypopnoea-index (AHI) as well as apnoea index (AI) dropped significantly immediately after successful cardioversion into stable sinus rhythm.  While SDB has been shown to be an independent risk factor for rhythm control therapy, this study reveals an effect of successful rhythm control (restoring of sinus rhythm from Afib/Aflu) on SDB. Further studies are needed to prove context and impact of rhythm control in patients with atrial fibrillation and atrial flutter regarding their characteristics of sleep-disordered breathings for their respective status of rhythm.
Medicolegal pitfalls in the treatment of borderline patients
Authors: Thomas G. Gutheil
Journal: American Journal of Psychiatry (1985)

Patients with the borderline syndrome, although not always the sickest patients, often cause the most difficulty because of their intense and contagious affects, their often impulsive behavior, and the strains they place on the treaters' countertransference. The author explores the hitherto ignored area of medicolegal problems that often arise in treatment of borderline patients. Specifically, he addresses the issues of legal ignorance of the syndrome, the effect of dynamic processes such as splitting and psychotic transference, problems regarding limit setting and related management approaches, and problems arising from countertransference phenomena. He suggests approaches to these problems as well.
Matrix metalloproteinases, IL-8 and glutathione in the prognosis of workers exposed to chlorine
Authors: K. Maghni, J.‐L. Malo, J. L’Archevêque, L. Castellanos, D. Gautrin
Journal: Allergy (2009)

Workers exposed to chlorine may be at risk of deterioration in FEV1.A prospective study of 72 workers examined over a 5.8 +/- 1.9 year period. A sample of induced sputum for cells and mediators was obtained in 69 subjects at baseline (Vb) and in 36 both at Vb and at follow-up (Vf).Sixty-four workers (89%) experienced at least one accidental inhalation of chlorine in the interval. The mean decrease in FEV1 was 30 ml/year and thus was within normal limits. Among the analysed remodelling markers, the level of the MMP-9-TIMP-1 complex, but not of free MMP-9 and TIMP-1, significantly diminished from Vb to Vf. We found significant correlations between neutrophils, IL-8, MMP-9 and MMP9-TIMP-1 complex at Vb and Vf. While levels of total glutathione, IL-8, MMP9, TIMP-1 and MMP9-TIMP-1 complex were highly correlated with each other at Vb, this was inconstant at Vf. Levels of MMP9-TIMP1 complex and of TIMP1 at Vf were significantly lower in workers reporting chlorine puffs with mild acute respiratory symptoms between visits compared to those who had no, or asymptomatic inhalations (P = 0.03 and 0.02, respectively). The fall in FEV1 from Vb to Vf was significantly correlated with levels of glutathione at Vb. Cough between visits was associated with a decrease in FEV1 (P = 0.06).Although no accelerated loss in FEV1 was documented in these workers exposed to chlorine, subjects with a greater fall in FEV1 were more likely to report cough and have higher levels of total glutathione at Vb.
Infant lung function and subsequent respiratory morbidity during the first year of life in preterm infants
Authors: Elena Proietti, Thomas Riedel, Oliver Fuchs, Isabelle Pramana, Philipp Latzin, Urs Frey
Journal: European Respiratory Journal (2011)

Compared to term-born infants, preterms reveal more respiratory symptoms and alterations in lung function. We aimed to investigate whether in preterms lung function parameters obtained near term correlate with respiratory morbidity during the first year of life.  Lung function (tidal breathing flow-volume loops, multiple-breath washout) was measured using an ultrasonic flowmeter in a cohort of N=263 unsedated preterm infants at mean±SD 44.9±0.2 weeks of gestational age during natural sleep according to latest ERS/ATS standards. The cohort included preterm infants (28% without, 22% with mild, 32% moderate, 16% severe bronchopulmonary dysplasia) selected randomly mainly due to logistic constraints. We retrospectively assessed respiratory morbidity in the first year of life (wheeze, rehospitalisation, inhalation and oxygen therapy) using a standardized questionnaire (recall rate 70%). We computed uni- and multivariable logistic regression adjusted for known confounders.  We found sporadic associations between lung function parameters and outcomes that reached statistical significance, but no clear overall relationship. The strongest association was found for TPTEF/TE e.g. with inhalation therapy: OR 0.92 CI 0.87-0.98.  In this cohort of preterm infants lung function tests performed without sedation do not result in additional benefit for the prediction of respiratory morbidity during the first year of life. Reasons for that might be the pre-selected cohort, the limitations of retrospective assessment of symptoms or the large variability of the lung function measurements reflecting the clinical status.
Aprepitant use in children, adolescents and young adults for the control of chemotherapy induced nausea and vomiting (CINV)
Authors: M. Choi, C. Jiles, N. L. Seibel
Journal: Journal of Clinical Oncology (2008)

20558 Background: One of the most common and distressing side effects for cancer patients is CINV. New anti-emetics, such as aprepitant (Apr), have been reported to improve control of this side effect, particularly in adults. However, very little is known about its effect in the pediatric oncology population, with only 5 reported cases of Apr used in adolescents and none in children < 16 years of age. Methods: Retrospective chart review on the use of Apr in the pediatric oncology population receiving highly emetogenic chemotherapy in our pediatric institution. Results: 37 charts (18 males and 19 females) were reviewed. Mean age was 13 years (range from 32 months-23 years). Highly emetogenic chemotherapy (cyclophosphamide or cisplatin) was used in 27/37 and moderately emetogenic chemo (ifosfamide, daunorubicin and/or doxorubicin) in 7/37. Anti-emetic regimens consisted of Apr + 5-HT3 RA + dexamethasone (Regimen 1, 26/37 patients) or Apr +5-HT3 RA (Reg. 2, in 11/37). Aprepitant was started on day 1 of chemotherapy at 125 mg po, followed by 80 mg on days 2 and 3 in 29/37 patients; 7/37 received 80 mg daily x 3 days, starting on day 1, and 1/37 received 80 mg on day 1, followed by 40 mg on days 2 and 3. 10/37 patients were chemotherapy-naïve and received Apr on their first cycle. Of these, 7/10 reported minimal or no CINV. In 27/37, Apr was added later in their treatment, with 14/27 reporting resolution of CINV after its addition. 7/37 patients reported no resolution of their symptoms, and of these, 4 consistently experienced anticipatory as well as delayed N/V throughout their treatment, and were described as extremely anxious. 2/4 received Apr on days 1–3 of their first cycle. The other 3/7 found that other combinations of anti-emetics had better resolution of their symptoms. 9/37 patients used Apr only once and no further information about the decision to stop its use was available in their charts. Conclusions: Aprepitant when combined with standard anti-emetics such as 5-HT3 RA and dexamethasone, improved CINV in the pediatric oncology population studied in our retrospective chart review. However, there is still a need to conduct prospective studies to determine the optimal efficacy and safety of aprepitant in the pediatric oncology population. No significant financial relationships to disclose.
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
Authors: J R Daniels, L Y Chak, B I Sikic, P Lockbaum, M Kohler, S K Carter, R Reynolds, R Bohnen, D Gandara, J Yu
Journal: Journal of Clinical Oncology (1984)

One hundred forty-seven eligible patients with small-cell carcinoma of the lung (SCCL) have been randomized to receive alternating (A) or sequential (S) combination chemotherapy. Initial treatment was with three cycles of VAM (A) or two cycles of POCC (S). VAM consists of VP16-213 200 mg/m2 intravenously (IV) day 1, Adriamycin (Adria Laboratories, Columbus, Ohio) 50 mg/m2 IV day 1, and methotrexate 30 mg/m2 IV day 1 repeated at 21-day intervals. POCC consists of cyclophosphamide 600 mg/m2 IV days 1 and 8, vincristine 1.5 mg/m2 (maximum, 2 mg) IV days 1 and 8, CCNU 60 mg/m2 po day 1, and procarbazine 100 mg/m2 po days 2 through 15. After initial treatment, all patients received whole brain radiation therapy (3,000 rad/10 fractions/2 wk). Patients with limited disease in addition received irradiation encompassing the tumor, hilar, mediastinal, and supraclavicular regions (5,000 rad/25 fractions/5 wk). After radiation, patients on arm A received POCC alternating with VAM; patients on arm S received POCC until progression when they were to be treated with VAM. The alternating arm was superior with respect to rate of complete remission (CR), median disease-free survival (MDFS), and median survival (MS). The advantage of alternating therapy was not as clearly demonstrated in the limited disease groups when interposition of involved field radiation delayed the initiation of the alternating schedule. In limited disease alone, comparing arm A with arm S, no statistically significant differences were noted. The CR rate was 42% v 54%, MDFS was 14 v 10 months, and MS was 16 v 10 months. In extensive disease, the CR rate was 44% v 20% (P = .03), MDFS was 6 v 4 months (P = .003), and MS was 10 v 7 months (P = .001). Improved treatment outcome in SCCL is achieved when combination chemotherapy regimens of similar effectiveness are administered in an alternating rather than sequential schedule.
Diagnostic and prognostic significance of survivin levels in malignant pleural effusion
Authors: Didem Görgün, Funda Seçik, Kenan Midilli, Vakur Akkaya, Pinar Yildiz
Journal: European Respiratory Journal (2011)

We aimed to evaluate the diagnostic and prognostic value of measuring survivin levels which is an inhibitor of apoptosis in pleural effusions.   Methods:  Group I, malignant (MPE) (n=53); Grup II, tuberculosis (TPE) (n=18); Group III transudative (TE) (n=9) effusions were enrolled prospectively. We used ELISA to analyze 80 effusions for survivin. The accuracy of diagnosis and the correlation between survivin and survival in MPE were analyzed.   Results:  Survivin level was 40.32±75.06 in MPE, 15.83±10.92 in TPE and 8.33±8.67 in TE. According to survivin level there was no istatistical significant difference between study groups. (p=0.182). When the patients divided two group as malignant and non-malignant pleural effusion, survivin level was significantly higher in MPE (40.32±75.06) than in non-MPE (13.33±2.05) (p=0.011). The cut-off value for survivin levels detected by ROC curve analysis was 7.5 pg/ml, with sensitivity and specifity values of%72,%44, respectively. There was no correlation between survivin level and age, sex, location, fluid pH, glucose, protein, albumine and ADA level while there was significant correlation with fluid LDH. (r=0.045; p  In conclusion, survivin expression levels detected with ELISA can be usefull for the differential diagnosis of MPE and non-MPE despite TPE can cause false positive results in high prevalent countries. Specifity and sensitivity results could be better when cases of tuberculosis has been ruled out. Further studies are needed which included larger group of patients with other exudative effusions.